Roble Belko & Company’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $125K | Hold |
279
| – | – | 0.02% | 162 |
|
|
2025
Q4 | $126K | Hold |
279
| – | – | 0.02% | 155 |
|
|
2025
Q3 | $109K | Hold |
279
| – | – | 0.01% | 139 |
|
|
2025
Q2 | $124K | Hold |
279
| – | – | 0.02% | 128 |
|
|
2025
Q1 | $135K | Hold |
279
| – | – | 0.02% | 121 |
|
|
2024
Q4 | $112K | Sell |
279
-63
| -18% | -$29.2K | 0.02% | 132 |
|
|
2024
Q3 | $159K | Hold |
342
| – | – | 0.03% | 111 |
|
|
2024
Q2 | $160K | Hold |
342
| – | – | 0.03% | 112 |
|
|
2024
Q1 | $143K | Hold |
342
| – | – | 0.02% | 117 |
|
|
2023
Q4 | $139K | Hold |
342
| – | – | 0.03% | 107 |
|
|
2023
Q3 | $119K | Hold |
342
| – | – | 0.02% | 112 |
|
|
2023
Q2 | $120K | Hold |
342
| – | – | 0.02% | 109 |
|
|
2023
Q1 | $108K | Hold |
342
| – | – | 0.02% | 120 |
|
|
2022
Q4 | $99K | Hold |
342
| – | – | 0.02% | 126 |
|
|
2022
Q3 | $99K | Hold |
342
| – | – | 0.02% | 122 |
|
|
2022
Q2 | $96K | Hold |
342
| – | – | 0.02% | 128 |
|
|
2022
Q1 | $89K | Sell |
342
-12
| -3% | -$2.85K | 0.02% | 138 |
|
|
2021
Q4 | $78K | Hold |
354
| – | – | 0.01% | 136 |
|
|
2021
Q3 | $64K | Hold |
354
| – | – | 0.01% | 134 |
|
|
2021
Q2 | $71K | Hold |
354
| – | – | 0.02% | 142 |
|
|
2021
Q1 | $76K | Hold |
354
| – | – | 0.02% | 129 |
|
|
2020
Q4 | $84K | Hold |
354
| – | – | 0.02% | 118 |
|
|
2020
Q3 | $96K | Buy |
354
+12
| +4% | +$3.31K | 0.03% | 110 |
|
|
2020
Q2 | $99K | Hold |
342
| – | – | 0.03% | 116 |
|
|
2020
Q1 | $81K | Hold |
342
| – | – | 0.03% | 123 |
|
|
2019
Q4 | $75K | Hold |
342
| – | – | 0.02% | 138 |
|
|
2019
Q3 | $58K | Hold |
342
| – | – | 0.02% | 140 |
|
|
2019
Q2 | $63K | Hold |
342
| – | – | 0.02% | 138 |
|
|
2019
Q1 | $63K | Hold |
342
| – | – | 0.02% | 110 |
|
|
2018
Q4 | $57K | Hold |
342
| – | – | 0.02% | 109 |
|
|
2018
Q3 | $66K | Hold |
342
| – | – | 0.02% | 98 |
|
|
2018
Q2 | $58K | Hold |
342
| – | – | 0.02% | 105 |
|
|
2018
Q1 | $56K | Buy |
342
+47
| +16% | +$7.68K | 0.02% | 114 |
|
|
2017
Q4 | $44K | Buy |
+295
| New | +$43.7K | 0.02% | 119 |
|
|
2017
Q2 | – | Sell |
-23
| Closed | -$3K | – | 351 |
|
|
2017
Q1 | $3K | Hold |
23
| – | – | ﹤0.01% | 296 |
|
|
2016
Q4 | $2K | Buy |
+23
| New | +$1.87K | ﹤0.01% | 330 |
|
Other funds holding VRTX
VCM
VPM
Roble Belko & Company's VRTX Position: Q1 2026 in Review
Roble Belko & Company held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 279 shares worth $125K. The position accounts for 0.02% of the portfolio, ranked #162.
Roble Belko & Company first reported a position in VRTX in Q4 2016 and has held it in 36 quarters since. The position peaked at $160K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Roble Belko & Company held 279 shares of Vertex Pharmaceuticals worth $125K as of Q1 2026.
- Roble Belko & Company left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
- Vertex Pharmaceuticals made up 0.02% of Roble Belko & Company's portfolio in Q1 2026, its #162 holding.
- Roble Belko & Company first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 36 quarters since.
- Roble Belko & Company's Vertex Pharmaceuticals position peaked at $160K in Q2 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Roble Belko & Company's 13F filing for Q1 2026, filed 16 Apr 2026.